Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- Hiroshi Kasamoto Named as Bioverativ Japan President
January 20, 2017
- JCR to Initiate PI/II Study in March of Therapeutic Enzyme for Hunter Syndrome that Applies Blood-Brain Barrier Technology
January 20, 2017
- Ethical Drug Sales Down 3.6% in November: Crecon Report
January 19, 2017
- Gilead Japan to Switch Sovaldi, Harvoni Bottles to Blister Packs
January 19, 2017
- Nichi-Iko, Meiji Seika Pharma Obtain New Indications for Zosyn Generics
January 19, 2017
- Gilead Asks Pharmacists to Open Harvoni Bottles in Front of Patients after Fake Drug Found
January 18, 2017
- Mitsubishi Tanabe to Shake Up Organization in April
January 17, 2017
- Eisai to Take Over Rights to Roche/Chugai’s Insomnia Drug
January 17, 2017
- FDA Orphan Status Granted to Nippon Shinyaku’s DMD Med
January 17, 2017
- Dasotraline Meets Primary Endpoint in PII/III Study in Adult Patients with Binge Eating Disorder: Sumitomo Dainippon
January 17, 2017
- Hisamitsu Suffers Double-Digit Plunge in March-November Sales
January 16, 2017
- Shionogi’s Novel Antibacterial Shows Effectiveness in Urinary Tract Infection
January 13, 2017
- SBI Biotech Licenses Autoimmune Disease Med to Kyowa Kirin
January 13, 2017
- Takeda Invests US$125 Million in Maverick for T-Cell Therapy, Buyout Eyed
January 13, 2017
- AbbVie’s 8-Week Hep C Med Delivers High SVR12 Rate in Japanese
January 13, 2017
- Imigran AG to Get Off Strong Start: Aspen Japan
January 12, 2017
- Astellas Bows Out from Flu Vaccine Development Pact with UMN
January 11, 2017
- Daiichi Sankyo to Shutter Indian Research Subsidiary
January 11, 2017
- Plavix AG Now Has All Same Indications as Originator
January 11, 2017
- Daiichi Sankyo Gets Japan Rights to Kite’s CAR T-Cell Therapy
January 11, 2017
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…